Roxane Laboratories, Inc. v. Tracy

1996 Ohio 180, 74 Ohio St. 3d 654
CourtOhio Supreme Court
DecidedMarch 1, 1996
Docket1994-2045
StatusPublished

This text of 1996 Ohio 180 (Roxane Laboratories, Inc. v. Tracy) is published on Counsel Stack Legal Research, covering Ohio Supreme Court primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Roxane Laboratories, Inc. v. Tracy, 1996 Ohio 180, 74 Ohio St. 3d 654 (Ohio 1996).

Opinion

[This opinion has been published in Ohio Official Reports at 74 Ohio St.3d 654.]

ROXANE LABORATORIES, INC., APPELLANT, v. TRACY, TAX COMMR., APPELLEE. [Cite as Roxane Laboratories, Inc. v. Tracy, 1996-Ohio-180.] Taxation—Sales and use taxes—Equipment used to perform Federal Food and Drug Administration testing on samples of a pharmaceutical batch taken after the packaging and sale of the remainder of the batch not exempt. (No. 94-2045—Submitted December 12, 1995—Decided March 1, 1996.) APPEAL from the Court of Appeals for Franklin County, Nos. 93APH12-1721 and 93APH12-1722. __________________ {¶ 1} Roxane Laboratories, Inc. (“Roxane”), appellant, contests the appellee Tax Commissioner’s assessments of sales and use taxes on various items of equipment used for stability testing. The assessments involved the audit periods of January 1, 1983, through December 31, 1985, and January 1, 1986, through December 31, 1988. Both the Board of Tax Appeals (“BTA”) and the court of appeals upheld the assessments. {¶ 2} Roxane manufactures generic pharmaceutical products. Roxane does not develop new prescription pharmaceuticals itself. Rather, it waits until an innovative new drug patent has expired and develops a product for sale based upon the expired patent. Because the drugs produced by Roxane have been previously approved by the Federal Food and Drug Administration (“FDA”), Roxane is not required to obtain re-approval of the effectiveness or medicinal value of these drugs. Roxane is, however, required by the FDA to procure pre-approval of each drug it intends to manufacture. {¶ 3} In order to obtain this re-approval, Roxane is required by the FDA to test the stability of the drugs it manufactures. The purpose of testing for stability SUPREME COURT OF OHIO

(“stability testing”) is to verify, at set intervals of time, that the drugs have not become ineffective or chemically broken down. The FDA requires that stability testing be done (1) prior to FDA approval in order to develop a protocol for manufacturing the product and to establish future testing procedures, and (2) after the drug is packaged and marketed to assure its continued efficacy by monitoring the product during its expected shelf life. In dispute is the equipment Roxane uses in its stability testing of the packaged drugs. {¶ 4} In order to conduct the required on-going stability testing, samples from each pharmaceutical batch are drawn off from the manufacturing process as the product goes into the package and are monitored and tested using the stability testing equipment. If the stability tests are not satisfactory, the drug is deemed adulterated and must be recalled. Stability testing is not performed on the drugs as they are being manufactured, nor does the testing indicate whether the drugs were manufactured properly. {¶ 5} Roxane timely appealed the assessments on the stability testing equipment to the BTA. In affirming the assessments, the BTA found that the stability testing was performed either before any manufacturing had begun or after the drug had been packaged and sold, and therefore the stability testing equipment was not entitled to exception under R.C. 5739.01(E)(2) as items used directly in manufacturing. Roxane appealed and the court of appeals affirmed the BTA’s decision on this issue. {¶ 6} The cause is now before this court pursuant to an allowance of a discretionary appeal. __________________ Brickler & Eckler and Mark A. Engel; and Brian E. Andreoli, pro hac vice, for appellant. Betty Montgomery, Attorney General, and Richard C. Farrin, Assistant Attorney General, for appellee.

2 January Term, 1996

__________________ COOK, J. {¶ 7} The issue before this court is whether equipment used to perform FDA testing on samples of a pharmaceutical batch taken after the packaging and sale of the remainder of the batch is exempt from sales and use taxes as an adjunct to manufacturing pursuant to R.C. 5739.01(E)(2). We find that equipment used in stability testing does not qualify as an adjunct to manufacturing under R.C. 5739.01(R), as it is used after manufacturing ends. {¶ 8} Roxane challenges the failure to exempt the stability testing machinery from sales and use taxes as an adjunct to manufacturing. Because the use tax adopted the sales tax exemptions, we will address only the sales tax statutes, but the analysis applies equally to the use tax. See R.C. 5741.02(C)(2). {¶ 9} Roxane contends that, because the stability testing is required by the FDA, the testing is part of the manufacturing process, and is therefore exempted from sales tax by former R.C. 5739.01(E)(2), which provided: “‘Retail sale’ *** include[s] all sales except those in which the purpose of the consumer is: “ *** “(2) *** to use or consume the thing transferred directly in the production of tangible personal property * * * for sale by manufacturing, processing ***.” (140 Ohio Laws, Part II, 3216.) {¶ 10} In order for this manufacturing exemption to apply, a taxpayer must meet the definition of “manufacturing” provided in former R.C. 5739.01(R) (now 5739.01[S]). During the audit periods in question, the General Assembly focused repeatedly on this definition and changed the language of the statute several times;

3 SUPREME COURT OF OHIO

however, the concept never changed. The legislative changes only clarified the concept by further defining the statutory terms.1 {¶ 11} From November 24, 1981 until March 12, 1987, R.C. 5739.01(R) provided: “‘Manufacturing’ or ‘processing’ means the transformation or conversion of material or things into a different state or form from that in which they originally existed and, for the purpose of the exceptions contained in division (E)(2) of this section, includes the adjuncts used during and in, and necessary to carry on and continue, production to complete a product at the same location after such transforming or converting has commenced.” (139 Ohio Laws, Part II, 3250.) {¶ 12} From March 13, 1987, until October 20, 1987, R.C. 5739.01(R), as amended by Am. H.B. No. 159, 142 Ohio Laws 2109, 2114-2115, provided: “(R)(1) ‘Manufacturing’ or ‘processing’ means the transformation or conversion of material or things into a different state or form from that in which they originally existed. Manufacturing or processing begins at the point where the transformation or conversion commences, or at the point where raw materials are committed to the manufacturing process in a receptacle by being measured, mixed, or blended, whichever occurs first, and it ends when the product is completed. “(2) For the purpose of the exceptions contained in division (E)(2) of this section, things used or consumed directly in manufacturing or processing include the adjuncts used during and in, and necessary to carry on and continue, production to complete a product at the same location after transforming or converting has commenced and before it has ended. Adjuncts include, but are not limited to, machinery and equipment that generates heat or power for production processes and foundations and supports for machinery and equipment used during

1. Following the audit periods in question, R.C. 5739.01 was amended. We do not address these later amendments because they are not relevant to the time period in question.

4 January Term, 1996

manufacturing. Machinery and equipment used before manufacturing begins or after manufacturing ends as described in this division are neither used directly in manufacturing nor as adjuncts. “(3) For the purpose of the exceptions contained in division (E)(2) of this section, the fact alone that machinery or equipment, supplies, or services are necessary, essential or crucial to the manufacturing process does not mean they are used directly in the manufacturing process or as an adjunct.” (New language emphasized.) {¶ 13} From October 20, 1987, through April 10, 1990, R.C. 5739.01(R)(2), as amended by Am. Sub. S.B. No.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Pfeiffer v. Jenkins
46 N.E.2d 767 (Ohio Supreme Court, 1943)
Hawthorn Mellody, Inc. v. Lindley
417 N.E.2d 1257 (Ohio Supreme Court, 1981)
OAMCO v. Lindley
493 N.E.2d 1345 (Ohio Supreme Court, 1986)
OAMCO v. Lindley
500 N.E.2d 1379 (Ohio Supreme Court, 1986)
OAMCO v. Lindley
503 N.E.2d 1388 (Ohio Supreme Court, 1987)
Jeep Corp. v. Limbach
547 N.E.2d 975 (Ohio Supreme Court, 1989)
Meridian Technology Leasing Corp. v. Tracy
653 N.E.2d 232 (Ohio Supreme Court, 1995)
Roxane Laboratories, Inc. v. Tracy
660 N.E.2d 1190 (Ohio Supreme Court, 1996)

Cite This Page — Counsel Stack

Bluebook (online)
1996 Ohio 180, 74 Ohio St. 3d 654, Counsel Stack Legal Research, https://law.counselstack.com/opinion/roxane-laboratories-inc-v-tracy-ohio-1996.